Replies to post #107531 on Biotech Values

[turtlepower]

You beat me to the punch. Actually from what i can remember shire withdrew the FDA application and was planning to resubmit data. I can't remember them submitting data after that.

GSK got better revenue sharing terms than Shire did.

[mcbio]

In addition, Shire already had ERT in both Gaucher (approved this year) and Fabry (pending at FDA).

That's true, but I assume Shire's ERT for Fabry isn't oral like Amigal. Also, the failure in Gaucher may have raised some questions about FOLD's Fabry drug succeeding. But, they are two completely different drugs I believe. Perhaps the main reason was the failure of FOLD's Gaucher drug and that larger market opportunity being off the table as you noted.